9,07 $
12,45 % gestern
Nasdaq, 7. Oktober, 22:08 Uhr
ISIN
US1856341029
Symbol
CLNN
Berichte

Clene Inc Aktie News

Neutral
GlobeNewsWire
13 Tage alt
Late-breaking clinical data presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis Across non-active progressive MS (primary progressive and secondary progressive MS), relapsing MS, and Parkinson's disease patients, CNM-Au8 ® improved the brain's energy metabolism evidenced by improved NAD+/NADH ratio At the Type B end-of-Phase 2 MS meeting wit...
Neutral
GlobeNewsWire
etwa ein Monat alt
SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurological diseases, today announced new preclinical data showing that CNM-Au8® improved key me...
Neutral
GlobeNewsWire
etwa ein Monat alt
SALT LAKE CITY, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that manageme...
Neutral
GlobeNewsWire
etwa 2 Monate alt
SALT LAKE CITY, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced its second qua...
Neutral
GlobeNewsWire
etwa 2 Monate alt
SALT LAKE CITY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management wil...
Neutral
GlobeNewsWire
2 Monate alt
SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that managemen...
Neutral
GlobeNewsWire
3 Monate alt
FDA provides supportive feedback on proposed statistical analysis plan for neurofilament biomarker analysis of Clene's NIH-sponsored Expanded Access Program NfL EAP biomarker analyses to be conducted early in the 4 th Quarter of 2025 Clene confirms two additional FDA meetings scheduled for 3 rd Quarter of 2025, to discuss ALS survival data and MS clinical development program Submission of new d...
Neutral
Accesswire
4 Monate alt
SALT LAKE CITY, UT / ACCESS Newswire / June 9, 2025 / Clene Inc. announced that Rob Etherington, Chief Executive Officer and President, will be presenting at the Investor Summit Virtual taking place on June 10. About Clene Inc. Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical com...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen